Dorneyville Pharmacy – FDA 483, Sep 28, 2018

This FDA Form 483 document outlines observations made during an inspection, indicating deficiencies in the firm's operations related to drug manufacturing.

Observation 1 notes the failure to establish adequate procedures for the cleaning and maintenance of equipment. This suggests a potential risk of cross-contamination or equipment malfunction, which could impact product quality and safety.

Observation 2 identifies that the firm did not adequately validate the manufacturing process for Drug X. Process validation is a critical requirement to ensure that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. The lack of adequate validation raises concerns about the consistency and quality of Drug X.

Observation 3 states that the firm did not maintain proper records of batch production and control. Accurate and complete batch records are essential for traceability, quality control, and demonstrating compliance with Good Manufacturing Practices (GMP). This deficiency could hinder investigations into product quality issues and prevent a comprehensive review of manufacturing operations.

Collectively, these observations point to significant issues within the firm's quality system and manufacturing processes, particularly concerning equipment management, process control, and documentation. These findings imply potential regulatory non-compliance and could have business and operational implications, including the need for corrective actions to address the identified deficiencies and ensure adherence to regulatory standards.